Mitral valve articles

Resultados alentadores en la válvula mitral percutánea en los pacientes complejos

TENDER Study, Evolution at One Year

TENDER Study, Evolution at One Year

The use of transcatheter mitral valve intervention for the treatment of mitral valve regurgitation (MR) continues to evolve; at present guidelines only recommend it for inoperable or high surgical risk patients.    So far, many devices have been assessed, some of which have shown promising results, but only for poor surgical candidates.  Researchers looked into the

La insuficiencia renal post tratamiento borde a borde tricuspídeo impacta en el pronóstico

Edge-to-Edge Repair in Cardiogenic Shock

The edge-to-edge approach with MitraClip has been established as a valid strategy for patients who experience severe symptomatic mitral regurgitation (MI) with high risk for surgery, currently with a IIa indication. MI complicated by cardiogenic shock, which results in a high risk for conventional valve surgery, is a particularly complex scenario. In such a case,

Costo efectividad de la reparación endovascular y quirúrgica en aneurismas complejos

Promising Results of Transcatheter Mitral Valve Replacement in Bioprosthesis Failure

Failure of a mitral bioprosthesis always poses a challenge regarding decision-making, especially when dealing with elderly patients with multiple risk factors. The scenario is worsened by the high risk associated with a new sternotomy and the significant impact of undergoing new surgery. Transcatheter mitral valve-in-valve (TMViV) replacement is emerging as a valid strategy in the

Transcatheter Mitral Valve Replacement: DOAC or VKA?

Severe mitral disease is common and currently constitutes a frequent cause of hospitalization and death. While surgery is the treatment of choice, transcatheter mitral valve replacement (TMVR) emerges as a valid alternative in cases of bioprosthesis failure, ring malfunction, or severe mitral annular calcification (MAC). Furthermore, the latest medical guidelines support the recommendation of TMVR

La insuficiencia renal post tratamiento borde a borde tricuspídeo impacta en el pronóstico

Health Status Scores after Transcatheter Repair in Patients with Tricuspid Regurgitation: TRILUMINATE Analysis

Severe tricuspid regurgitation (TR) has been associated with higher mortality and significant limitations to patient quality of life, with considerable rates of hospitalization for cardiac failure (CF). Transcatheter edge-to-edge repair (TEER) with TriClip has been shown effective to reduce symptoms, with low risk of periprocedural complications.  The aim of this study was to assess functional

New Advances in Mitral Regurgitation Devices with Promising Results

Mitral regurgitation (MR) is a frequent valvulopathy and when the optimal medical treatment at maximum tolerated doses is not enough, surgery is the first course of action. And even though edge-to-edge repair with clips has seen substantial improvement, it is currently reserved for those at high risk of surgery.  However, there is an increasing number

TCT 2023 | ALIGN AR trial

TCT 2023 | CLASP IID Study 1-Year Results: PASCAL vs. MITRACLIP for Degenerative Mitral Regurgitation

The negative impact of mitral regurgitation (MR) on patient mortality, morbidity, and quality of life is widely recognized. However, only 15% of patients are referred for surgery due to their high surgical risk and low ejection fraction. Transcatheter edge-to-edge repair has become an important alternative for this group of patients. For subjects with degenerative MR,

TCT 2023 | ALIGN AR trial

TCT 2023 | TRILUMINATE Trial: Health Status after TriClip

Severe tricuspid regurgitation (TR) has been associated with higher mortality, increased risk of hospitalization for cardiac failure (CF), reduced functionality and poor health status.  Tricuspid edge-to-edge repair (T-TEER) with TriClip effectively reduces TR with low risk of post-procedural complications.  The TRILUMINATE Pivotal trial (Trial to Evaluate Cardiovascular Outcomes in Patients Treated with the Tricuspid Valve

TCT 2023 | ALIGN AR trial

TCT 2023 | EXPAND G4

The EXPAND G4 is a prospective multicenter single arm study on real life patients.  It included a total 1,164 patients with primary (PMR) and secondary (SMR) mitral valve regurgitation treated with MitraClip G4. Research was carried out at multiple locations across US, Europe, the Middle East and Japan.  Key outcomes assessed aspects such as all-cause

Resultados alentadores en la válvula mitral percutánea en los pacientes complejos

MITRAL Trial, Results at 5 Years

Repeat mitral valve repair has been associated with increased mortality. Transcatheter mitral valve repair has surged as an alternative for patients treated with mitral valve-in-valve (MViV), valve-in-ring (MViR), or valve-in-mitral for annular calcification (ViMAC). Current data from the VIVID and the MAC Global Registry on 30-day evolution in these 3 scenarios show 7.4%, 11.4% and

La insuficiencia renal post tratamiento borde a borde tricuspídeo impacta en el pronóstico

TRILUMINATE Two Years In: Encouraging Results

Tricuspid valve regurgitation is more common than one might think. It often stems from left valve disease and associated with increased mortality and hospitalization due to heart failure, which is not easy to treat. Currently, guidelines list surgery as the recommended treatment, though this option is quite complex and might entail complications and mortality risk.

Top